Stroke Certification Less Likely in the Most Disadvantaged Communities
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, July 30, 2024 -- Hospitals located in the most disadvantaged communities have a lower likelihood of adopting any stroke certification, according to a study published online July 25 in JAMA Network Open.
Renee Y. Hsia, M.D., from the University of California in San Francisco, and colleagues conducted a cohort study to examine whether hospitals in socioeconomically disadvantaged communities are less likely to adopt stroke certification using newly collected stroke center data. A total of 5,055 hospitals were studied from 2009 to 2022, of which 47.8, 11.9, and 40.3 percent never achieved stroke certification, were certified as acute stroke-ready hospitals, and were certified as primary stroke centers or higher, respectively.
The researchers found that adoption of any stroke certification was most likely to occur near the most advantaged communities and was least likely near the most disadvantaged communities compared with mixed-advantage communities (hazard ratios, 1.24 and 0.43, respectively). Mixed-advantage communities were most likely to have adoption of acute stroke-ready certification, while adoption of higher-level certification was more likely in the most advantaged communities and least likely in the most disadvantaged communities (hazard ratios, 1.41 and 0.31, respectively). The stroke certification adoption hazard was lower for relatively disadvantaged communities and for the most disadvantaged communities compared with mixed-advantage communities (adjusted hazard ratios, 0.80 and 0.58, respectively), after adjustment for population size and hospital capacity.
"Given increasing evidence showing that stroke-certified hospitals are associated with improved care, incentivizing and providing support for hospitals in disadvantaged communities to obtain stroke certification may serve as an important strategy for reducing stroke disparities," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-31 01:15
Read more
- Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
- Clinical Practice Guidelines Updated for Primary Prevention of Stroke
- Alcohol-Induced Liver Disease Hospitalizations, Transplants on the Rise
- Expanded Admission Screening Protocol for Candida Auris Beneficial
- Heat Waves Linked to Adverse Health Outcomes for Seniors
- About 1 in 10 U.S. Adults Have High Cholesterol
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions